Archives
Dehydroepiandrosterone (DHEA) Research Workflows
2026-10-01
Build reproducible DHEA workflows for neural survival, stem-cell expansion, and PCOS-related ovarian studies. This guide connects formulation, dose selection, macrophage–granulosa assays, and troubleshooting to the latest evidence on CD163-associated inflammation.
Proteinase K for DNA and EV Workflows
2026-09-30
Proteinase K supports high-integrity genomic DNA preparation, enzyme contaminant removal, and controlled protein-accessibility assays in extracellular vesicle research. This practical guide connects robust digestion conditions with Candida albicans EV experiments while emphasizing controls, optimization, and interpretation limits.
DHEA Workflows for PCOS and Neuroprotection
2026-09-30
Learn how to use DHEA as both a PCOS-modeling tool and a mechanistic probe for ovarian and neural survival studies. This workflow separates disease induction from protective-dose testing while improving solubility, timing, controls, and assay interpretation.
Prochlorperazine: From Receptor Biology to Assay Design
2026-09-29
Prochlorperazine is a dopamine D2 receptor antagonist with applications spanning antiemetic therapy, melanoma research, and mechanistic cell biology. This article converts its pharmacology and a route-sensitive dopaminergic study into practical guidance for selecting endpoints, concentrations, controls, and translational boundaries.
ABE9-SpRY for Bystander-Free Mouse Models
2026-09-29
The reference study combines the ABE9 adenine base editor with PAM-flexible SpRY Cas9 nickase to improve precise A-to-G editing in mouse embryos and human induced pluripotent stem cells. ABE9-SpRY generated three of four targeted mouse mutations, reached up to 96% desired editing in individual adult founders, and showed improved product purity and fewer detected off-target events than ABE8e-SpRY at the tested loci.
Dimetridazole: Evidence and Research Workflows
2026-09-28
Dimetridazole, also called 1,2-Dimethyl-5-nitroimidazole, is a nitroimidazole research compound for anaerobic, protozoal, quorum-sensing, and analytical studies. Its most precise quantitative benchmark is an electrochemical molecularly imprinted sensor with a reported 0.1 nM detection limit under optimized differential-pulse voltammetry conditions.
Dehydroepiandrosterone (DHEA) Research Workflows
2026-09-28
Use Dehydroepiandrosterone (DHEA) to investigate steroid-sensitive cell growth, apoptosis inhibition and neuronal stress responses—with distinct dose windows for acute and longer-term assays. This guide separates DHEA experiments from a recent ferulic-acid study of chemotherapy-induced ovarian injury, turning that study’s validation strategy into practical assay-design ideas without conflating the compounds.
BIIE 0246 and the Y2R–Y1R Evidence Boundary
2026-09-27
BIIE 0246 is a potent neuropeptide Y Y2 receptor antagonist for probing receptor-specific signaling. This article explains how to use Y2R pharmacology to interpret, rather than overextend, findings on the adipose-neural axis and cardiac arrhythmia.
Targeted Amikacin Delivery into Mycobacterial Granulomas
2026-09-26
The study tested whether dendritic cells could carry fluorescently labeled amikacin into Mycobacterium avium granulomas in mice, addressing the challenge of reaching organisms sequestered in infected tissue. The findings support targeted delivery as a preclinical approach, but establish localization rather than improved infection control or clinical benefit.
ATRX Loss and RTK Inhibitor Sensitivity in Glioma
2026-09-25
A drug screen reported that ATRX-deficient high-grade glioma cells were more sensitive to several multi-targeted receptor tyrosine kinase inhibitors and platelet-derived growth factor receptor inhibitors than ATRX-proficient comparators. The study also found pronounced toxicity with combined RTK-inhibitor and temozolomide treatment in ATRX-deficient cells, supporting ATRX status as a biomarker to evaluate in further preclinical and clinical research—not as a proven treatment-selection rule.
Nullscript and Placental Ferroptosis: A Research Framework
2026-09-25
Nullscript is a histone deacetylase inhibitor with a distinctive transcriptional profile. This article connects its established research context to a placental nanoplastic study—and explains how to test that cross-domain hypothesis without mistaking a useful experimental probe for an established treatment.
GOB-38 in E. anophelis: Activity and Substrate Range
2026-09-24
The study characterizes GOB-38, a metallo-β-lactamase from Elizabethkingia anophelis, and reports activity across penicillins, cephalosporins, and carbapenems. Its biochemical findings, together with clinical co-isolation and co-culture experiments, highlight questions about resistance in mixed infections while leaving the mechanism and extent of any interspecies transfer to be resolved.
Cefepime in Plasmid-Mediated Resistance Research
2026-09-24
Cefepime (BMY-28142) can help researchers examine how mobile resistance genes reshape beta-lactam susceptibility. This article interprets recent Enterobacter cloacae transmission findings as practical guidance for building more informative genotype–phenotype assays.
Hyperforin Activates Dlat–Trpv3 Adipose Thermogenesis
2026-09-23
A 2025 study reports that hyperforin promotes adipose thermogenesis through a Dlat-dependent Trpv3–calcium–Camkkb–AMPK pathway, providing a mechanistic alternative to canonical β3-adrenergic signaling. Mouse, cell-based, and pharmacokinetic experiments support further investigation, while leaving human efficacy and long-term safety unresolved.
Fumagillin Workflows for Angiogenesis Research
2026-09-23
Fumagillin is a mechanistically defined methionine aminopeptidase-2 inhibitor for connecting endothelial cell assays with pathogen-focused screening. This practical guide emphasizes fresh solution handling, evidence-aligned dose finding, comparative controls, and the limits of translating aquatic parasite results into cancer research.